Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ACR Appropriateness Criteria® Recurrent Lower Urinary Tract Infections in Females: Update 2026.

Journal of the American College of Radiology : JACR·2026

Same author

Peripheral serotonin contributes to testosterone and estradiol induced urinary voiding dysfunction in adult male mice.

American journal of clinical and experimental urology·2026

Same author

ACR Appropriateness Criteria® Penetrating Trauma-Abdomen and Pelvis: Update 2026.

Journal of the American College of Radiology : JACR·2026

Same author

A poly(A) isoform-aware single-cell and spatial atlas defines fibroblast niches in the human bladder.

bioRxiv : the preprint server for biology·2025

Same author

Toward Consistent and Actionable MRI Reporting for Prostate Cancer Staging.

AJR. American journal of roentgenology·2025

Same author

Estrogen regulation in the prostate underlies racial disparity in men with benign prostatic hyperplasia.

The Journal of pathology·2025

Search research articles

Related Experiment Video

Updated: Feb 24, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Douglas W Strand¹, Daniel N Costa², Franto Francis³

¹Department of Urology, University of Texas Southwestern Medical Center, USA.

Differentiation; Research in Biological Diversity

|August 12, 2017

Summary

This summary is machine-generated.

Benign prostatic hyperplasia (BPH) treatment is challenging due to cellular differences between patients. Understanding these unique BPH phenotypes is key to developing effective, personalized therapies.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Feb 24, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

Urology
Cell Biology
Pathology

Background:

Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) affect many elderly males, with limited medical treatment options.
Current therapies, including alpha blockers and 5-alpha reductase inhibitors, have not significantly improved clinical outcomes since their introduction.
Pathological heterogeneity, characterized by unique cellular phenotypes in individual patients, is an underappreciated factor hindering the development of novel BPH targets.

Purpose of the Study:

To review strategic experimental approaches for understanding the cellular pathogenesis of distinct BPH phenotypes.
To discuss the incorporation of these cellular insights into clinical practice for improved patient outcomes.
To address the failure of developing targeted therapies for personalized medicine due to a lack of cellular and molecular understanding of BPH phenotypes.

Main Methods:

This review synthesizes current research on the cellular and molecular basis of BPH.
It outlines experimental strategies to dissect the heterogeneity of BPH phenotypes.
The review discusses the translation of cellular findings into clinical applications.

Main Results:

BPH exhibits significant pathological heterogeneity at the cellular level.
Individual patient phenotypes are composed of distinct cell types, contributing to varied disease presentation.
A deeper cellular understanding is crucial for advancing personalized medicine in BPH treatment.

Conclusions:

Unraveling the cellular pathogenesis of discrete BPH phenotypes is essential for therapeutic advancement.
Integrating cellular and molecular insights holds the potential to improve treatment outcomes for BPH.
Addressing pathological heterogeneity is critical for developing targeted therapies and personalized medicine for BPH.